ArticleBMC complementary medicine and therapies2025
The potential of novel gut microbiota supplement in mitigating gut inflammation, alleviating oxidative stress linked to aging, and improving cognitive function in aged mice.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Correction: The potential of novel gut microbiota supplement in mitigating gut inflammation, alleviating oxidative stress linked to aging, and improving cognitive function in aged mice.BMC complementary medicine and therapies · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
Abstract
backgroundAging is a physiological process that impacts multiple systems of organs. Alzheimer's disease (AD) is the most common form of dementia in the elderly, and it is a major problem in aging societies. The development of AD is linked to an accumulation of amyloid beta and Tau proteins, which impair cognition and cause memory loss. PURPOSE: We studied whether probiotics strains could protect and how effectively probiotics might delay age-related changes.
methodsTwo probiotics, Lactobacillus paracasei MSMC39-1 and Bifidobacterium animalis MSMC83 strain, were administered orally to mice beginning in middle age and continuing into aged mice. The mice were subsequently monitored and assessed for inflammation and oxidative stress in the colon, brain, and liver tissues, as well as for overall health, over a period of 16 weeks.
resultsWe found aged mice received the combination of these probiotics showed a lower level of inflammatory markers and improved overall health compared to the control group. MSMC39-1 and MSMC83 enhance gut integrity and general well-being in aged mice and result in improved cognitive memory.
conclusionOur findings suggest that these probiotics supplements may be particularly useful in strategies for the prevention of age-related pathologies by reducing inflammation and oxidative stress, which in turn would slow disease progression. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.